Fisher & Paykel Healthcare Corp Ltd reports rapid growth: Should you buy?

Are today's results a 'Buy' sign for Fisher & Paykel Healthcare Corp Ltd (ASX:FPH)?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Not too long ago, I wrote that Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)("FPH") was trading 'above what a prudent investor (one seeking a margin of safety) would ideally pay for the shares'. In price to earnings (P/E) terms, Fisher & Paykel is nearly 30% more expensive than CSL Limited (ASX: CSL), but today's results show just why the market loves it.

Here are Fisher & Paykel's highlights for the 12 months to 31 March 2016:

(All figures are in NZ$ unless indicated otherwise)

  • Revenue grew 21% to $815.5 million (up 14% in constant-currency terms)
  • Net Profit After Tax (NPAT) grew 27% to $143.4 million (up 15% in constant-currency)
  • Dividends of 10 cents per share (8 cents per share last year)
  • Investment in R&D increased by 13%, is now 9% of operating revenue
  • Gross margins widened by 2.8% (operating margins grew by 0.6%)
  • North America is the fastest growing region, up 33%, while Europe, Asia Pacific and Other grew mid-teen percentages or less
  • Gearing was 7.7%, outside target range of -5% to +5% (debt to debt plus equity)
  • Debt of $65 million, cash of $14 million
  • 83% of revenue comes from recurring items, consumables, and accessories

So What?

There's a lot of information to digest if you're an FPH shareholder. Key elements are the company's products, which address unmet medical needs such as humidification for invasive ventilation. It has one product named, Optiflow, which has been found to reduce the need for intubation, re-intubation and increase ventilator free days.

Having products whose effects are validated by medical literature and which contribute to improved patient quality of life and reduced cost/staff demands is a great way to ensure hospitals keep buying those products. Fisher & Paykel released a bullish growth outlook (more on that below) and believes a significant increase in margins will be possible over the next few years, ultimately leading to more profits for shareholders.

A strong tailwind is growing demand in developed markets, currently estimated at US$6 billion, although developing nations are also seeing demand growth. Chinese healthcare expenditures are expected to triple (from 2012) by 2020. Fisher & Paykel is also using its masks to take market share from incumbents, which speaks to the quality of its products.

Now What?

Fisher & Paykel guided for revenue of approximately $900 million and NPAT of $165 million to $170 million in 2017, at current exchange rates. Based on management's recent history of under-promising and over-delivering, this could be a reasonable forecast. If accurate, it would mean that Fisher & Paykel is trading on a PE ratio of around 32, which is closer to CSL, but still more expensive.

The company also operates in a competitive segment with a number of companies such as ResMed Inc. (CHESS) (ASX: RMD) and Somnomed Limited (ASX: SOM) operating in overlapping or related fields. However, FPH has a massive, growing portfolio of patents (page 28 of the presentation) which will help protect it from imitation.

Based on these results and the outlook for its target market, Fisher & Paykel looks likely to justify today's price and could in fact be a buy for the patient investor.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »